Altoven Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.20 Cr
as on 16-11-2024
- Paid Up Capital ₹ 1.20 Cr
as on 16-11-2024
- Company Age 4 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.22 M
as on 16-11-2024
- Revenue %
(FY 2023)
- Profit -368.96%
(FY 2023)
- Ebitda -314.13%
(FY 2023)
- Net Worth -97.91%
(FY 2023)
- Total Assets 144.33%
(FY 2023)
About Altoven Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.20 Cr and a paid-up capital of Rs 1.20 Cr.
The company currently has active open charges totaling ₹3.22 M.
Murugan Sean, Prabakaran Sankaralingam, Nehrudassan Rajamani, and Five other members serve as directors at the Company.
- CIN/LLPIN
U24110TN2020PTC135338
- Company No.
135338
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 May 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Altoven Pharmaceuticals?
Board Members(8)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Murugan Sean  | Director | 09-Apr-2022 | Current |
| Prabakaran Sankaralingam | Director | 03-Oct-2020 | Current |
| Nehrudassan Rajamani | Director | 09-Apr-2022 | Current |
| Vengatesan Manian | Director | 09-Apr-2022 | Current |
| Lakshmanan Rajamani | Director | 09-Apr-2022 | Current |
| Natarajan Ilangovan | Director | 10-Dec-2021 | Current |
Financial Performance of Altoven Pharmaceuticals.
Altoven Pharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 368.96% decrease in profit. The company's net worth observed a substantial decline by a decrease of 97.91%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Altoven Pharmaceuticals?
Unlock access to Altoven Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Cassel Research Laboratories Private LimitedActive 26 years 1 monthMurugan Sean, Nehrudassan Rajamani and 2 more are mutual person
- Lessac Research Laboratories Private LimitedActive 20 years 3 months
Murugan Sean and Lakshmanan Rajamani are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 28 Feb 2024 | ₹3.22 M | Open |
How Many Employees Work at Altoven Pharmaceuticals?
Altoven Pharmaceuticals has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Altoven Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Altoven Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
